Considerations for Peripheral Blood Stem Cell Apheresis in a Low Body Weight Infant

Background:Low weight children can sometimes be selected as donor in HSCT. Donor with thalassemia minor has low MCV, which affects peripheral blood stem cell (PBSC) harvest. It is worthwhile to explore a harvest program for donors with low body weight and low MCV. Objective:The aim of this study is to find out an appropriate program of PBSC collection in children with low body weight and low MCV. Methods:10 children, with median age of 2 (1-6) years, average weight of 13.4 (9.5- 20) kg and average MVC value of 63fl (54-78)) were hospitalized in our center from October 2018 to July 2019 for stem cell mobilization. Donor weight were less than recipients in 7 cases. 5 donors have 5 kg less than recipient, 3 have 10 kg less and 1 has 18 kg less, respectively. They received G-CSF of 5 mg/kg/d twice a day for 5 days before harvest. 500 ml ACD-A solution and 3000 IU heparin were mixed and given by the ratio of 1 ml mixed anticoagulant versus 24 ml whole blood. Blood-flow was 25-40 ml/min. Results:More 20/ul CD34+ cells were harvested in 9 cases (90%), and 19.2/ul in 1 case (10%). Median nucleated cells were13.2(6.7-22.4)x108/kg in donor weightand 9.8 (8.3-13.9) x108/kg in recipient weight. The median CD34+ cells were 5 (1.9-10.2) x106/kg in donor weight and 3.4 (1.4-9.7) x106/kg in recipient weight. The coagulation function was normal in reexamination. PBSC were harvested only once in all donors. Average circulating volume was 2.48 (1.14-5.79) total body volume, average harvesting time was 2.75 (2-6) hours, and average PBSC volume was 89 (63-160) ml. Donor peripheral blood calcium and potassium ion concentration showed no obvious abnormality. Conclusion:Combination of citrate and heparin can be well used to collect PBSC in donors with low body weight and low MCV. All children were well tolerance to the program, which was safe and effective for large volume collection of PBSC. Disclosures No relevant conflicts of interest to declare.

Download Full-text

Feasibility of peripheral blood stem cell (PBSC) and peripheral blood mononuclear cell (PBMNC) separation in children with a body weight below 20 KG

Medical and Pediatric Oncology ◽

10.1002/(sici)1096-911x(199708)29:2<115::aid-mpo9>3.0.co;2-h ◽

1997 ◽

Vol 29 (2) ◽

pp. 115-120 ◽

Cited By ~ 22

Author(s):

Christian Urban ◽

Wolfgang Schwinger ◽

Martin Benesch ◽

Herwig Lackner ◽

Reinhold Kerbl ◽

...

Keyword(s):

Body Weight ◽

Stem Cell ◽

Peripheral Blood Mononuclear Cell ◽

Mononuclear Cell ◽

Peripheral Blood ◽

Peripheral Blood Stem Cell ◽

Blood Stem Cell ◽

Peripheral Blood Mononuclear

Download Full-text

Comparison of autologous peripheral blood stem cell dosing by ideal vs actual body weight

Bone Marrow Transplantation ◽

10.1038/sj.bmt.1701731 ◽

1999 ◽

Vol 23 (9) ◽

pp. 867-873 ◽

Cited By ~ 15

Author(s):

JM Waples ◽

JS Moreb ◽

M Sugrue ◽

G Belanger ◽

P Kubilis ◽

...

Keyword(s):

Body Weight ◽

Stem Cell ◽

Actual Body ◽

Peripheral Blood ◽

Peripheral Blood Stem Cell ◽

Blood Stem Cell ◽

Actual Body Weight

Download Full-text

High-activity samarium-153-EDTMP therapy followed by autologous peripheral blood stem cell support in unresectable osteosarcoma

Nuklearmedizin ◽

10.1055/s-0038-1625284 ◽

2001 ◽

Vol 40 (06) ◽

pp. 215-220 ◽

Cited By ~ 33

Author(s):

S. Bielack ◽

S. Flege ◽

J. Eckardt ◽

J. Sciuk ◽

H. Jürgens ◽

...

Keyword(s):

Stem Cells ◽

Stem Cell ◽

High Activity ◽

Peripheral Blood ◽

Peripheral Blood Stem Cell ◽

Blood Stem Cell ◽

High Dose ◽

External Radiotherapy ◽

Primary Tumor Site ◽

Hematopoietic Stem

Summary Purpose: Despite highly efficacious chemotherapy, patients with osteosarcomas still have a poor prognosis if adequate surgical control cannot be obtained. These patients may benefit from therapy with radiolabeled phosphonates. Patients and Methods: Six patients (three male, three female; seven to 41 years) with unresectable primary osteosarcoma (n = 3) or unresectable recurrent sites of osteosarcomas (n = 3) were treated with high-activity of Sm-153-EDTMP (150 MBq/kg BW). In all patients autologous peripheral blood stem cells had been collected before Sm-153-EDTMP therapy. Results: No immediate adverse reactions were observed in the patients. In one patient bone pain increased during the first 48 hrs after therapy. Three patients received pain relief. Autologous peripheral blood stem cell reinfusion was performed on day +12 to +27 in all patients to overcome potentially irreversible damage to the hematopoietic stem cells. In three patient external radiotherapy of the primary tumor site was performed after Sm-153-EDTMP therapy and in two of them polychemotherapy was continued. Thirty-six months later one of these patients is still free of progression. Two further patients are still alive. However, they have developed new metastases. The three patients who had no accompanying external radiotherapy, all died of disease progression five to 20 months after therapy. Conclusion: These preliminary results show that high-dose Sm-153-EDTMP therapy is feasible and warrants further evaluation of efficacy. The combination with external radiation and polychemotherapy seems to be most promising. Although osteosarcoma is believed to be relatively radioresistant, the total focal dose achieved may delay local progression or even achieve permanent local tumor control in patients with surgically inaccessible primary or relapsing tumors.

Download Full-text